List of Excipients in Branded Drug R-GENE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	R-GENE	arginine hydrochloride	0009-0436	HYDROCHLORIC ACID
Pharmacia & Upjohn Company LLC	R-GENE	arginine hydrochloride	0009-0436	WATER

R-GENE Excipient Strategy and Commercial Opportunities in Arginine Hydrochloride Injection

Last updated: September 6, 2026

R-GENE is a legacy intravenous arginine hydrochloride product used primarily as a diagnostic stimulus for growth hormone secretion. Its formulation is technically simple: a high-strength aqueous arginine hydrochloride solution with water for injection and acid used for pH adjustment. The commercial opportunity is therefore less likely to come from a complex excipient patent and more likely to come from supply reliability, ready-to-use presentation, container-closure performance, global registration, and differentiated clinical workflow.

The core product is generally described as a 10% arginine hydrochloride injection. A typical diagnostic dose is 0.5 g/kg, up to a 30 g maximum, administered by intravenous infusion over approximately 30 minutes. The product is hypertonic and requires controlled infusion and monitoring under the FDA labeling framework.[1]

What is R-GENE and how is it formulated?

R-GENE is an arginine hydrochloride injection used to evaluate growth hormone reserve. The active pharmaceutical ingredient is arginine hydrochloride, an amino-acid salt supplied in aqueous solution.

R-GENE formulation profile

Attribute	R-GENE formulation characteristic
Active ingredient	Arginine hydrochloride
Strength	10% w/v formulation
Route	Intravenous infusion
Primary use	Growth hormone stimulation testing
Principal solvent	Water for injection
pH control	Hydrochloric acid or equivalent acid adjustment
Preservative strategy	Preservative-free presentation is commercially preferable
Dosage form	Sterile parenteral solution
Administration	Dilution or controlled infusion may be required under labeling and institutional protocol
Main formulation risks	Hypertonicity, pH control, precipitation, particulate matter, container interaction, infusion-site reactions

The excipient burden is low. The principal formulation task is to maintain arginine hydrochloride in a stable, sterile, injectable solution while controlling pH, osmolality, particulate levels, and container compatibility. The FDA label identifies the product as an arginine hydrochloride injection rather than as a multi-excipient delivery system.[1]

What excipients should a commercial R-GENE formulation use?

A minimal-excipient formulation is the strongest starting point for an R-GENE follow-on product. Additional excipients would need a clear technical or commercial justification because the product is administered intravenously for a diagnostic procedure and is often used in pediatric populations.

Preferred excipient architecture

The preferred platform would contain:

1. Arginine hydrochloride as the active ingredient.
2. Water for injection as the vehicle.
3. Hydrochloric acid for pH adjustment.
4. No antimicrobial preservative.
5. No unnecessary buffer system.
6. No colorant, surfactant, or complexing agent unless required by stability data.

A low-excipient formulation reduces the risk of local irritation, incompatibility with infusion systems, extractables and leachables, and regulatory questions concerning intravenous exposure. It also supports a straightforward abbreviated application if the reference product and proposed product can be shown to be pharmaceutically equivalent and bioequivalent or otherwise clinically comparable under the applicable FDA pathway.[2]

Why a buffer may be commercially unattractive

A phosphate, citrate, acetate, or other buffer could improve pH resistance, but it would increase the formulation's ionic load and introduce additional compatibility questions. Because arginine hydrochloride is already a salt at a high concentration, a second buffer may increase osmolality and infusion-site tolerability risk.

A buffer could be justified if the proposed product has a meaningful pH-drift problem during sterilization or storage. That decision should be based on forced-degradation and long-term stability data, not on a presumption that a more complex formulation is superior.

Why preservatives are generally a weak strategy

A multidose preserved presentation could reduce packaging cost in some settings, but it is poorly aligned with a diagnostic intravenous product. Preservatives can create pediatric and intravenous safety concerns and may complicate hospital pharmacy acceptance. A single-dose, preservative-free container is more consistent with current parenteral quality expectations and with the likely use pattern of growth hormone stimulation testing.[3]

What technical controls are most important for R-GENE?

The critical quality attributes are solution clarity, pH, osmolality, assay, impurities, sterility, bacterial endotoxins, particulate matter, fill volume, and container-closure integrity.

pH and osmolality

Arginine hydrochloride injection is hypertonic. The formulation must balance chemical stability against infusion tolerability. An aggressive pH adjustment could reduce degradation in some conditions but increase the risk of local irritation or incompatibility with other intravenous products.

The commercial product should define a narrow, validated pH range and monitor osmolality across the shelf life. The product should not rely on dilution by the hospital unless the labeling and administration process clearly support that approach.

Sterilization strategy

Terminal sterilization is preferable where the formulation and container can tolerate the process. If terminal sterilization causes unacceptable degradation, a sterile-filtration and aseptic-fill process may be required. The development program should compare:

• Terminal sterilization versus aseptic processing.
• Glass vial versus polymer container.
• Standard closure versus coated elastomer.
• Single-dose vial versus flexible infusion bag.
• Nitrogen headspace versus conventional headspace.
• Light-protective packaging versus standard packaging.

A simple solution does not eliminate manufacturing risk. High-concentration amino-acid solutions can present challenges involving pH drift, discoloration, particulate formation, and interaction with elastomeric components.

Container-closure selection

The main commercial formats are:

Presentation	Commercial benefit	Main barrier
Single-dose glass vial	Familiar to hospitals; strong barrier properties	Requires transfer or pharmacy preparation
Ready-to-use infusion bag	Reduces preparation time and handling	Larger fill, higher shipping cost, bag-material compatibility
Polymer bottle	Lower breakage risk and easier logistics	Extractables, oxygen permeability, adsorption, and closure validation
Prefilled syringe	Supports controlled administration	High device cost and less natural fit for large diagnostic doses
Concentrate vial	Lower freight and storage burden	Requires dilution and creates medication-preparation steps

A 100 mL ready-to-use bag or bottle could be commercially attractive if it matches a common dose and reduces pharmacy workload. A larger dose may require more than one container for heavier patients, which weakens the value proposition. A single-dose vial may remain more practical for institutions that prepare individualized weight-based infusions.

What formulation patents could protect a new R-GENE product?

A basic arginine hydrochloride solution is unlikely to support a broad, durable composition-of-matter patent. The strongest protectable positions would likely involve a narrow technical combination or a delivery presentation.

Potential patentable subject matter

Potential claims could cover:

• A defined arginine hydrochloride concentration and pH range.
• A low-particulate formulation with specified impurity limits.
• A container made from a defined polymer or coated glass.
• A formulation with improved post-sterilization stability.
• A ready-to-use infusion bag with specified oxygen transmission properties.
• A formulation that remains within a defined osmolality range after storage.
• A terminally sterilized product with controlled degradation products.
• A packaging system that limits arginine adsorption or leachables.
• A dosing kit combining the injection, infusion set, and sampling schedule.
• A diagnostic kit using arginine hydrochloride with a specified growth hormone testing protocol.

These claims would face enablement, written-description, obviousness, and freedom-to-operate scrutiny. A narrow formulation patent may be useful commercially, but it would not necessarily block a competitor using a different container, pH range, manufacturing process, or presentation.

Manufacturing and process protection

Process patents may have greater practical value than formulation patents if they address:

• Removal of particulate matter.
• Control of arginine-related impurities.
• Sterilization without unacceptable degradation.
• Continuous compounding or high-concentration solution manufacture.
• Improved aseptic filling.
• Extended in-use stability after opening or dilution.
• Reduced container interaction.

Trade-secret protection may be more effective for process controls, supplier qualification, and impurity-management methods than a patent directed to a narrow aqueous solution.

When does R-GENE lose exclusivity and what is its Orange Book status?

R-GENE is a legacy small-molecule injectable product. Any original FDA marketing exclusivity would have expired long ago. Its commercial protection is therefore expected to depend on regulatory status, manufacturing capability, market availability, and hospital purchasing rather than on active new-drug exclusivity.

The Orange Book should be checked for the current reference-listed-drug designation, active abbreviated applications, patent listings, and exclusivity records before filing or investing. Orange Book status can change when FDA updates discontinued-product records or when an applicant enters or withdraws from the market.[4]

No active composition-of-matter or exclusivity position should be assumed solely from the brand's continued commercial presence. A follow-on applicant would need to assess:

• Whether R-GENE is currently listed as the reference standard.
• Whether an ANDA pathway is available.
• Whether the reference product has an active listing.
• Whether any patents are listed for the reference product.
• Whether a 505(b)(2) application is more appropriate because of presentation, concentration, or clinical-use differences.
• Whether FDA considers the product eligible for an abbreviated pathway based on the current regulatory record.

Are Paragraph IV challenges likely for R-GENE?

A Paragraph IV strategy would be relevant only if an ANDA applicant faces an unexpired listed patent. For a legacy arginine hydrochloride injection, the probability of a meaningful patent-based Paragraph IV dispute appears lower than for newer specialty drugs.

The principal entry risks are more likely to be regulatory and technical:

• Demonstrating pharmaceutical equivalence for a sterile solution.
• Matching concentration, route, dosage form, and labeling.
• Establishing container-closure integrity.
• Validating particulate and endotoxin controls.
• Obtaining a reliable source of pharmaceutical-grade arginine hydrochloride.
• Replicating the reference product's in-use and dilution characteristics.
• Addressing shortages or discontinued reference-product status.

A Paragraph IV settlement is therefore not the central commercial issue unless the Orange Book identifies a later-listed formulation or device patent. Any such patent would need to be assessed claim by claim for scope, expiration, and enforceability.

What commercial opportunities exist for R-GENE reformulation?

The largest opportunity is operational differentiation rather than pharmacological innovation.

Ready-to-use diagnostic infusion

A ready-to-use bag could reduce pharmacy compounding, calculation errors, and nursing preparation time. The product could be positioned around standardized dosing, bar-code compatibility, and reduced manipulation. The principal limitation is that weight-based dosing may require partial-volume administration or multiple units.

Pediatric-focused packaging

Growth hormone testing is commonly performed in pediatric endocrinology. A pediatric-oriented product could use:

• Smaller fill volumes.
• Clear dose markings.
• Low-sorption tubing compatibility.
• Unit-dose packaging.
• Child-specific labeling and preparation instructions.
• A kit format that integrates laboratory sampling time points.

The formulation itself would remain simple, but packaging and workflow claims could create commercial differentiation.

Hospital shortage and supply continuity

A reliable supplier could capture business even without patent exclusivity if the incumbent product is intermittently unavailable. Buyers may value:

• Dual-source API procurement.
• Domestic or regional fill-finish capacity.
• Long dated shelf life.
• Consistent vial or bag supply.
• Electronic ordering and bar-code support.
• Emergency allocation capability.

Shortage-driven opportunity is commercially real but volatile. It should not be treated as durable exclusivity.

International expansion

Arginine stimulation testing is used in endocrinology markets outside the United States, but registration requirements, approved indications, dosing practices, and diagnostic alternatives differ by jurisdiction. A global strategy would need country-specific review of:

• Injectable arginine product registrations.
• Pediatric diagnostic labeling.
• Pharmacopoeial requirements.
• Local GMP expectations.
• Import and cold-chain rules.
• Reimbursement for growth hormone testing.
• Availability of clonidine, glucagon, insulin tolerance testing, and macimorelin.

R-GENE does not require cold-chain distribution under its ordinary aqueous-injection profile, which can support expansion into markets with limited refrigerated logistics. Storage conditions and shelf life must be confirmed from the final stability program.[1]

How does R-GENE compare with competing growth hormone stimulation products?

R-GENE competes with diagnostic approaches rather than with another branded arginine formulation alone.

Diagnostic approach	Main commercial advantage	Main limitation
Arginine stimulation	Established intravenous stimulus; no insulin-induced hypoglycemia	IV access, infusion time, hypertonicity
Clonidine stimulation	Oral administration; no infusion required	Sedation and hypotension risks
Glucagon stimulation	Alternative when other tests are unsuitable	Longer testing process and gastrointestinal effects
Insulin tolerance test	Physiologically robust in selected settings	Hypoglycemia risk and intensive monitoring
Macimorelin	Oral ghrelin-receptor agonist; streamlined procedure	Product access, cost, and regulatory-market limitations

A new R-GENE presentation should therefore compete on workflow, safety handling, availability, and total procedure cost. A simple price reduction may not be sufficient if the product requires additional pharmacy preparation.

What litigation, licensing, and generic-entry risks affect R-GENE?

No major patent-litigation or licensing event should be presumed for a legacy arginine hydrochloride diagnostic injection without a current docket and Orange Book review. The likely commercial structure is open competition among manufacturers, distributors, and hospital suppliers.

Potential licensing opportunities include:

• API supply and quality agreements.
• Contract manufacturing for sterile fill-finish.
• Regional commercialization rights.
• Co-development of ready-to-use infusion bags.
• Bundled diagnostic kits with laboratory or endocrinology suppliers.
• Device partnerships for controlled infusion and dose measurement.

The main generic-entry scenario is a conventional sterile-solution entrant using a low-excipient formulation. The main differentiated-entry scenario is a 505(b)(2) product with a new container, ready-to-use format, dosing kit, or modified administration method.

How strong is the R-GENE patent estate?

The patent estate is likely weak as a blocking platform but potentially useful as a narrow improvement estate.

Patent category	Expected strength
Arginine hydrochloride active ingredient	Very weak; long-established compound
Basic aqueous injection	Weak; likely vulnerable to prior art
pH or osmolality window	Moderate only if linked to unexpected stability or tolerability
Container-closure system	Moderate where compatibility data support non-obvious benefits
Ready-to-use infusion presentation	Moderate, depending on claim scope and prior art
Manufacturing process	Potentially moderate to strong if difficult to reproduce
Diagnostic dosing kit	Moderate if the kit solves a defined workflow problem
Method-of-use patent	Limited unless tied to a specific patient-selection or testing protocol

The business case should not depend on broad patent exclusion. It should depend on regulatory execution, reliable supply, low total cost, and a clinically convenient presentation.

Key Takeaways

• R-GENE is a legacy arginine hydrochloride intravenous diagnostic product with a simple, low-excipient formulation.
• The preferred excipient strategy is arginine hydrochloride, water for injection, and acid pH adjustment, without preservatives or unnecessary buffers.
• The main technical risks are hypertonicity, pH drift, particulate formation, container interaction, and sterilization-related degradation.
• A ready-to-use infusion bag, pediatric-oriented package, or integrated diagnostic kit offers more commercial differentiation than a complex new excipient system.
• Original FDA exclusivity is long expired; current Orange Book status and active reference-product records must govern any ANDA or 505(b)(2) strategy.
• Paragraph IV risk is likely secondary to regulatory, manufacturing, and supply-chain barriers.
• Broad formulation patents are unlikely to provide durable exclusion. Narrow packaging, process, and workflow patents are more credible.
• Commercial value is tied to supply continuity, hospital labor reduction, global registration, and pediatric endocrinology workflow.

FAQs

Is R-GENE a biologic or a small-molecule drug?

R-GENE is a sterile small-molecule arginine hydrochloride injection. Biosimilar regulation does not apply. Competition would generally involve an ANDA, a 505(b)(2) application, or a jurisdiction-specific generic pathway.

Can a manufacturer add sodium chloride to an R-GENE formulation?

Sodium chloride could alter tonicity and compatibility but would increase the formulation's excipient and ionic burden. It would require a documented technical rationale, stability data, infusion-tolerability assessment, and regulatory justification.

Would a ready-to-use R-GENE bag need a new clinical trial?

Not necessarily. The requirement would depend on the proposed differences, regulatory pathway, labeling, dose presentation, and FDA determination. A materially different administration system or clinical-use claim could increase the evidentiary burden.

What is the most defensible patent strategy for an R-GENE follow-on product?

The strongest strategy is likely a layered portfolio covering container compatibility, sterilization, impurity control, ready-to-use presentation, and diagnostic workflow. A broad claim to arginine hydrochloride in water is unlikely to provide durable protection.

Is R-GENE suitable for a contract manufacturing partnership?

Yes. The product's formulation complexity is limited, but the partner must have validated sterile manufacturing, parenteral quality systems, container-closure testing, and experience with high-concentration amino-acid solutions.

References

1. U.S. Food and Drug Administration. (n.d.). R-GENE 10 (arginine hydrochloride injection, USP) prescribing information. FDA labeling database.

2. U.S. Food and Drug Administration. (2019). Draft guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.

3. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: General chapters for sterile preparations, particulate matter, bacterial endotoxins, and container-closure integrity. USP.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.